BMS 181174-d4
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for complete information.
BMS 181174-d4 Product Information
BMS 181174-d4 is listed under Stable Isotopes and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-97748.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
BMS 181174-d4
CAT No.
CS-T-97748
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C23H21D4N5O7S2
Molecular Weight
551.63
Category
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for complete information.
Description
Regulatory Description
BMS 181174-d4 is supplied with detailed characterization data compliant with regulatory guideline. BMS 181174-d4 can be used for analytical method development, method validation (AMV), Quality Control (QC), ANDA-related analytical work, and commercial pharmaceutical research applications.
Overview
"BMS 181174-d4 is labelled BMS 181174 (B595910), an analog of Mitomycin C (M371900) with activity against a range of tumour cell lines and xenografts, including MMC-resistant tumours. However, phase I clinical trials from Bristol-Myers Squibb demonstrated that the toxicity profile of BMS 181174 was no more favourable than that of mitomycin."
Synonyms
BMS 181174-d4
Application Notes
"BMS 181174-d4 is labelled BMS 181174 (B595910), an analog of Mitomycin C (M371900) with activity against a range of tumour cell lines and xenografts, including MMC-resistant tumours. However, phase I clinical trials from Bristol-Myers Squibb demonstrated that the toxicity profile of BMS 181174 was no more favourable than that of mitomycin."
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.